Summary: Evaluated eplerenone versus placebo in patients with heart failure (EF < 35%) and New York Heart Association functional class II symptoms. The primary composite endpoint of death from cardiovascular causes or first hospitalization for heart failure was reduced by 37% by eplerenone across all subgroups. All-cause mortality was reduced. There was a significant risk of hyperkalemia with eplerenone.

Original Publication:

N Engl J Med. 2011 Jan 6;364(1):11-21.

Eponym: Eplerenone in Mild Patients Hospitalization And SurvIval Study